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The prevalence of sleep disordered breathing (SDB) after acute myocardial infarction
(AMI) is high. However, little is known about predominant SDB type and the impact
of SDB severity on arrhythmogenesis. We conducted a prospective single-center
observational study and performed an unattended sleep study and Holter monitoring
within 10 days after AMI, and an unattended sleep study 11.3 months after AMI. All
patients were included from the Department of Cardiology at the University Hospital
Schleswig-Holstein, Lübeck, Germany. A total of 202 subjects with AMI (73.8% with
ST-elevation; 59.8 years; 73.8% male) were included. The mean BMI was 27.8 kg/m2
and the mean neck/waist circumference was 41.7/103.3 cm. The mean left ventricular
ejection fraction was 56.6%. The SDB prevalence defined as apnoea-hypopnea-index
(AHI) ≥ 5/h was 66.7% with 44.9% having central (CSA), and 21.8% obstructive sleep
apnoea (OSA). The mean AHI was 13.8 1/h. In 10.2% nsVT was detected in the Holter
monitoring. AI >23/h was independently associated with higher risk of nsVT in the
subacute AMI period. SDB is highly prevalent and CSA a predominant type of SDB
in the subacute phase after uncomplicated AMI treated with modern revascularization
procedures and evidence-based pharmacological therapy. Severe SDB is independently
associated with higher risk for nsVT in the subacute AMI period and its course should
be monitored as it can potentially have a negative impact on relevant outcomes of AMI
patients. Further prospective studies are needed to assess long-term follow up of SDB
after AMI and its impact on mortality and morbidity.
Keywords: central sleep apnoea, sleep disorder breathing, acute myocardial infarction, non-sustained ventricular
tachycardia, arrhythmogenesis
INTRODUCTION
Ischemic heart disease is one of the major causes of death worldwide. Introduction and
widespread use of modern revascularization procedures and evidence-based pharmacological
therapy improved the long-term prognosis after acute myocardial infarction (AMI) significantly
(1, 2). However, strategies to further improve the outcome of patients with AMI are highly welcome.
One strategy is to focus on the impact of comorbidities, such as sleep-disordered breathing (SDB).
SDB results in intermittent hypoxia (3), stress and sympathetic activation, which can negatively
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FIGURE 1 | Study flow chat. AMI–acute myocardial infarction.
influence the outcome of patients after AMI through induction
of myocardial oxidative stress (4), additional ischemic injury,
and limited recovery of left ventricular ejection fraction
(LVEF) (5). Several epidemiological studies demonstrated
high prevalence of SDB after AMI (6–9). Central sleep
apnoea (CSA) is a type of SDB common in patients with
congestive heart failure (10–12). Several pathophysiological
changes such as pulmonary congestion, impaired autonomic
function, and sympathetic hyperactivity, which occur after
AMI, are known causes of CSA (13, 14). However, reports
regarding CSA prevalence after AMI and its impact are
scarce (6, 15, 16), which is in part due to simple polygraphy
(PG) devices used without the opportunity to differentiate
between central, obstructive, or mixed apnoea events. We
conducted a prospective single-center study to observe the
prevalence of SDB and CSA in particular in the subacute
phase of AMI and to assess the impact of SDB severity on
the prevalence of non-sustained ventricular tachycardia (nsVT)
as a known predictor of sudden cardiac death in post-infarct
patients (17, 18).
MATERIALS AND METHODS
Study Collective and Design
This was a prospective observational study. We screened 1,935
patients with AMI, who were admitted to the Department of
Cardiology of the University Hospital of Lübeck, Germany,
between October 2006, and March 2009. Inclusion criteria were
defined as follows: confirmed AMI diagnosis (ST-elevation
myocardial infarction and non-ST-elevation myocardial
infarction) defined according to the criteria of European Society
of Cardiology (19, 20) with a completed coronary angiography,
and revascularized culprit vessel. Exclusion criteria were
defined as follows: patient not able or not willing to complete
written informed consent; hemodynamically or respiratory
instable subjects; concurrent therapy with oxygen; current SDB
therapy or previously diagnosed SDB based on the findings of
a polysomnography; age ≥ 80 years; dementia; severe chronic
obstructive lung disease; any current medication able to induce
central sleep apnoea; AMI event happened longer than 10 days
ago. From the 19,35 eligible patients 202 subjects who fulfilled
the inclusion criteria without any of the exclusion criteria were
included in the study protocol. All of them completed written
informed consent. The ethics committee of the University
Hospital of Lübeck, Germany, approved the study.
An unattended overnight sleep cardiorespiratory PG and a
Holter electrocardiography (ECG) over 24 h were performed
in the subacute phase of myocardial infarction (day 2–10).
Follow-up sleep study was performed in the long-term after
AMI. Demographic and medical data were collected from
medical records and patient interviews. Study schematic is shown
in Figure 1.
Sleep Monitoring
Initial unattended portable sleep monitoring was performed with
PolyMESAM R© (MAP, Munich, Germany), which is a validated
level 3 modified unattended portable sleep monitoring device
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(21). Heart rate and oxygen saturation were measured by finger
pulse oximetry, nasal/oral airflow by thermistor, chest, and
abdomen wall motion by inductance plethysmography, and body
position were recorded during sleep monitoring. Obtained data
were automatically analyzed with the device software in terms of
heart rate changes, desaturations, apnoea, and hypopnea events.
The findings were validated manually by study investigators
(AR, SP), who had received appropriate training in validating
the findings of PG, according to the American Academy of
Sleep Medicine (AASM) scoring recommendations (22). Event
TABLE 1 | Baseline characteristics of the study collective, sleep disordered
breathing (SDB) group and non-SDB group.
All patients Non-SDB SDB
(n = 202) (n = 66) (n = 132)
Age, years 59.8 ± 10.8 56.7 ± 9.5 61.7 ± 10.9¶
BMI, kg/m² 27.8 ± 4.0 26.1 ± 3.3 28.6 ± 4.0¶
Men, n (%) 149 (73.8) 45 (68.2) 101 (76.5)
History of CAD, n (%) 31 (15.4) 5 (7.6) 26 (19.7)
Previous CABG, n (%) 7 (3.5) 1 (1.5) 6 (4.5)
Previous MI, n (%) 23 (11.4) 4 (6.1) 18 (13.7)
Hypertension, n (%) 114 (56.4) 28 (42.4) 85 (64.4)¶
Diabetes mellitus, n (%) 33 (16.3) 6 (9.1) 27 (20.5)
Smoker, n (%) 118 (58.4) 47 (71.2) 67 (50.8)¶
Hyperlipidemia, n (%) 140 (69.3) 47 (71.2) 91 (68.9)
ß-blocker, n (%) 198 (98.0) 65 (98.5) 129 (97.7)
ACE inhibitor, n (%) 191 (94.6) 66 (100) 121 (91.7)*
ARB, n (%) 11 (5.4) 0 (0) 11 (8.3)
Calcium channel
blocker, n (%)
14 (6.9) 4 (6.1) 10 (7.6)
GBIIbIIIa receptor
blocker, n (%)
149 (73.8) 48 (72.7) 98 (74.2)
Systolic blood pressure
at admission, mmHg




80 [70–90] 80 [71–85] 80 [70–90]
Neck circumference,
cm
41.7 ± 3.7 40.4 ± 3.4 42.4 ± 3.6#
Waist circumference,
cm
103.3 ± 12.0 99.2 ± 10.6 105.6 ± 12.2#
Creatinine, µmol/l 74 [65–87] 72 [64–83] 75 [65–88]
CRP, mg/l 15.2 [5.5–42.2] 11.9 [3.8–30.9] 16.3 [6.9–49.6]
Leukocytes, 1/nl 8.6 [7.4–10.4] 8.6 [7.2–10.3] 8.6 [7.4–10.5]
Troponin T at
admission, µg/l
0.20 [0.06–0.54] 0.21 [0.06–0.57] 0.20 [0.06–0.54]
CKmax, U/l 1,255 [494–2,796] 1,369 [294–2,254] 1,243 [543–3,031]
CKMBmax, U/l 133 [45–265] 140 [39-232] 133 [49.5–280]
LDHmax,U/l 384 [224–663] 377 [185–608] 384 [233–690]
Continuous normally distributed variables are presented as mean ± standard
deviation; Continuous non-normally distributed variables are presented as median [25%
quartile−75% quartile]; ACE, angiotensin-converting enzyme; AHI- apnoea-hypopnea-
index; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery
bypass graft; CAD, coronary artery disease; CK, creatinine kinase; CVD, cardiovascular
disease; MI, myocardial infarction; *p < 0.05; ¶p < 0.01; #p < 0.001; Mann-Whitney U
test was used for non-normally distributed data.
duration was defined as the time from the nadir preceding
the first breath being significantly reduced to the beginning
of the first breath that approximates the baseline breathing
amplitude. A central apnoea event was defined as a complete
or almost complete (>90%) cessation of airflow for at least
10 s in the absence of chest and abdomen wall motion. An
obstructive apnoea event was defined as a complete or almost
complete (>90%) cessation of airflow for at least 10 s with
chest and/or abdomen wall effort. A hypopnea was defined as
a reduction in airflow of at least 30% from baseline associated
with a fall in oxygen saturation ≥ 3% from pre-event baseline
for at least 10 s. To express the severity of SDB, we calculated
the number of events per hour of sleep and defined as index:
apnoea-hypopnea-index (AHI), central (CAI), and obstructive
apnoeas per hour [obstructive apnoea index (OAI), and the total
number of hypopneas (hypopnea index (HI)]. The total sleep
duration was defined as a time with stable breathing pattern
in the sleep study. The severity of desaturation events during
sleep monitoring was expressed as the number of episodes of
desaturation below 90% per hour–oxygen desaturation index
(ODI). SDBwas diagnosed when AHI was equal to or higher than
five events per hour. We considered subjects having CSA when
more than 50% of apnoea events were classified as central or
having obstructive sleep apnoea (OSA), when more than 50% of
apnoea events were classified as obstructive according to AASM
criteria. Cheyne-Stokes respiration pattern was defined when
at least three cycles of crescendo and decrescendo change in
breathing amplitude occurred and CAI was five or more events
per hour.
Holter Monitoring
A 3-lead Holter monitoring (Tracker III, Reynolds, Hertford,
UK) was used. Obtained data were automatically analyzed with
the device software and validated manually by the experienced
study investigator (HB), who was blinded for the results of sleep
monitoring. nsVT was considered, when a run of at least three
consecutive ventricular beats with a rate more than 100 per
min and a whole event duration shorter than 30 s occurred.
Sustained VTwas considered when the event duration was longer
than 30 s.
The prevalence of high-grade tachycardic (nsVT, VT,
ventricular fibrillation) and bradycardic (AV block 2◦ and
3◦ and asystole) arrythmias was analyzed. Single ventricular
extrasystoles were not included in the final analysis. The impact
of SDB on the high-grade arrhythmia type with the highest
incidence was then analyzed.
Statistical Analysis
Statistical analysis was conducted with a commercially available
software package (SPSS version 13.0; SPSS Inc., Chicago,
USA). Continuous variables are shown as mean ± standard
deviation (SD). Categorical variables are shown as numbers
and percentages. Continuous variables were tested for normal
distribution with the Kolmogorov-Smirnov test. T-test was used
to compare normally distributed continuous variables. In case the
normal distribution was not present, Mann-Whitney U-test was
used for the comparison. Chi square test was used to compare
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TABLE 2 | Specific cardiological characteristics of the study collective, sleep disordered breathing (SDB) group and non-SDB group.
All patients Non-SDB SDB
(n = 202) (n = 66) (n = 132)
1-vessel-CAD, n (%) 59 (29.2) 28 (43.1) 30 (22.7)¶
2-vessel-CAD, n (%) 69 (34.2) 22 (33.8) 46 (34.8)
3-vessel-CAD, n (%) 73 (36.1) 15 (23.1) 56 (42.4)*
STEMI, n (%) 145 (71.8) 49 (74.2) 92 (69.7)
NSTEMI, n (%) 57 (28.2) 17 (25.8) 40 (30.3)
Anterior MI, n (%) 88 (43.6) 28 (42.4) 58 (43.9)
Non-Anterior MI, n (%) 114 (56.4) 38 (57.6) 74 (56.1)
Culprit lesion vessel, n (%)
LAD
81 (40.1) 26 (40.6) 54 (40.9)
RCA 78 (38.6) 26 (40.6) 51 (38.6)
LCX 41 (20.3) 12 (18.8) 27 (20.5)
Pain-to-ballon time, min 244 [172–600] 223 [150–371] 457[225–520]*
Pain-to-ballon time > 24 h, n (%) 34 (16.8) 10 (15.5) 22 (16.7)
Angiographic EF, % 56.8 [47.8–64.6] 60.0 [50.3–65.5] 60.0 [50.3–65.5]
Echocardiographic EF, % 55.5 [48.3–63.0] 59.0 [50.0–67.3] 55.0 [48.0–60.0]
Fractional Shortening, % 32.0 [25.0–38.0] 34.0 [27.0–39.0] 30.0 [25.0–36.3]
ESLVD, cm 3.4 ± 0.7 3.4 ± 0.5 3.4 ± 0.7
EDLVD, cm 5.0 ± 0.7 5.0 ± 0.6 4.9 ± 0.7
Primary PCI, n (%) 192 (95.0) 60 (92.3) 128 (97.0)
Continuous normally distributed variables are presented as mean ± standard deviation; Continuous non-normally distributed variables are presented as median [25% quartile−75%
quartile]; AHI, apnoea-hypopnea-index; CAD, coronary artery disease; LAD, left anterior descending coronary artery; MI, myocardial infarction; LCX, left circumflex artery; PCI,
percutaneous coronary intervention; RCA, right coronary artery; *p < 0.05; ¶p < 0.01; Mann-Whitney U test was used for non-normally distributed data.
categorical variables. Binary logistic regression was used to assess
the impact of SDB on arrhythmogenesis. “nsVT occurrence” was
used as a dependent dichotomous variable (“yes” if at least one
nsVTwas detected in theHoltermonitoring and “No,” if no nsVT
events were detected in the Holter monitoring). All available
demographic, cardiovascular, and sleep study parameters were
consecutively inputted in the univariate regression analysis as
independent variables. EF was converted in a dichotomous
variable as EF <35% (“yes” vs. “no”), as severely impaired EF has
major effect on the incidence of CSA. For SDB severity indices
with significant impact on nsVT occurrence in univariate tests
different cut-off values were further tested for their impact on
nsVT occurrence. Parameters which showed significant impact
on nsVT occurrence in the univariate tests were entered into
multivariate regression analysis, whereby SDB severity indices
were inputted as values above the cut-off, which was significant in
the univariate test. A two-sided p-value of <0.05 was considered
statistically significant. No adjustment was made for multiplicity.
RESULTS
Two hundred and two subjects were included in the study. Mean
age of the study collective was 59.8 years and the mean BMI
27.8 kg/m 2.73.8% were male. 56.4% had hypertension, 16.3%
diabetes mellitus, 69.3% hyperlipidemia, and 58.4% smoked at
the time of study inclusion. Mean measured waist circumference
was 103.3 cm and the mean neck circumference was 41.7 cm at
the study inclusion. The mean age of SDB-group was 61.7 years
and significantly higher than in non-SDB-group (56.7 years).
FIGURE 2 | Prevalence of the different apnoea-hypopnea-index (AHI) ranges
in the study collective.
The mean BMI in SDB-group was 28.6 kg/m2 and significantly
higher than in non-SDB-group. The prevalence of hypertension
was significantly higher in the SDB-group (64.4 vs. 42.4%,
respectively). Significantly more subjects smoked in the non-
SBD-group (71.2 vs. 50.8%, respectively). The neck and waist
circumference were significantly higher in the SDB-group (42.4
vs. 40.4 cm and 105.6 vs. 99.2 cm, respectively). Further baseline
characteristics for the whole study collective, SDB- and non-SDB
groups, are shown in Table 1.
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TABLE 3 | Sleep study characteristics of the whole study collective, sleep
disordered breathing (SDB)- and non-SDB-group.
All patients Non-SDB SDB
(n = 198) (n = 66) (n = 132)
AHI, events per
hour




1.8 [0.6–5.6] 0.5 [0.2–1.0] 3.8 [1.4–10.4]#
CAI, events per
hour
1.1 [0.4–4.2] 0.4 [0.1–0.66] 2.3 [0.8–8.5]#
OAI, events per
hour
0.4 [0.1–1.3] 0.1 [0.0–0.3] 0.8 [0.3–1.9]#
HI, events per
hour
5.1 [2.9–10.2] 2.3 [1.2–3.2] 8.6 [5.1–14.4]#
ODI, events per
hour
10.0 [4.0–19.0] 4.0 [3.0–5.3] 14.0
[9.0–24.0]#
Mean SpO2, % 93 [92–94] 94 [92–95] 93 [92–94]
Lowest SpO2, % 83 [80–86] 85 [83–88] 81 [77–85]#
Time spent with







Continuous non-normally distributed variables are presented as median [25%
quartile−75% quartile]; AI, apnoea index; AHI, apnoea-hypopnea-index; CAI, central
apnoea index; HI, hypopnea index; OAI, obstructive apnoea index; ODI, oxygen
desaturation index; SpO2, peripher oxygen saturation; *p < 0.05; #p < 0.001; Mann-
Whitney U test was used for non-normally distributed data.
Ninety five percentage of the included patients were
treated by primary percutaneous coronary intervention, which
included angioplasty and stenting. The majority of included
subjects had a ST-elevation myocardial infarction (71.8%).
The mean ejection fraction was 55.1%. Subjects in the
SDB-group had significantly higher rates of angiographically
confirmed Triple-Vessel coronary artery disease (42.4 vs. 23.1%,
respectively) and significantly lower rates of Single-Vessel
coronary artery disease compared to non-SDB group (22.7
vs. 43.1%). Further specific cardiological characteristics for the
whole study collective, SDB-, and non-SDB-group, are given
in Table 2.
Two-thirds of the study cohort (66.7%) had SDB with
44.9% of them having CSA and 21.8% OSA. Ten percentage
had Cheyne-Stokes respiration pattern. The mean AHI was
13.8 1/h, the mean AI was 6.0 1/h, the mean CAI was 4.7
1/h, the OAI was 1.3 1/h, and the mean HI was 7.8 1/h.
43.4% of the study subjects had between 5 and 20 AHI events
per hour. 11.4% of the SDB-group had >30 AHI events
per hour. Prevalence of the different AHI-ranges is shown
in Figure 2. The mean oxygen saturation was 93.0% and the
lowest oxygen saturation was 81.4%. The mean ODI was 14.3
1/h. Compared to the non-SDB-group, subjects in the SDB-
group had significantly lower mean oxygen saturation (92.7 vs.
93.7%), significantly higher ODI (19.3 1/h vs. 4.3 1/h) and spent
significantly more time with oxygen saturation <90% (4,096
vs. 592 s). Detailed sleep study characteristics for the whole
study collective, both the SDB-, and non-SDB-groups, are given
in Table 3.
Valid overnight polygraphy study andHolter monitoring were
available in 193 patients. The incidence of atrial fibrillation was
TABLE 4 | Baseline, cardiovascular and sleep study characteristics of the patients
with and without non-sustained ventricular tachycardia (nsVT).
no nsVT (n = 173) nsVT (n = 20)
Male, n (%) 128 (74.0) 15 (75.0)
Age, years 59.7 ± 10.7 64.1 ± 9.1
BMI, kg/m2 27.8 ± 3.9 27.9 ± 4.2
Previous MI, n (%) 21 (12.2) 1 (5.0)
Hypertension, n (%) 95 (54.9) 17 (85.0)*
Diabetes mellitus, n (%) 25 (14.5) 8 (40.0)¶
Current Smoker, n (%) 100 (57.8) 11 (55.0)
Hyperlipidaemia, n (%) 119 (68.8) 14 (70.0)
1-vessel-CAD, n (%) 53 (30.6) 4 (21.1)
2-vessel-CAD, n (%) 61(35.3) 6 (31.6)
3-vessel-CAD, n (%) 59 (34.1) 9 (47.3)
Ejection fraction, % 57 [50–63] 51 [45–59]
Systolic diameter of the left chamber, cm 3.3 [2.9–3.7] 3.5 [3.2–4.1]
Diastolic diameter of the left chamber, cm 5.0 [4.5–5.4] 5.0 [4.3–5.4]
AHI, events per hour 8.4 [4.0–19.0] 15.1 [3.5–32.0]
AI, events per hour 1.7 [0.6–5.1] 2.8 [0.9–25.0]
cAI, events per hour 1.0 [0.3–3.6] 1.7 [0.6–20.0]
oAI, events per hour 0.4 [0.1–1.3] 1.0 [0.2–2.3]
HI, events per hour 5.5 [3.0–10.2] 4.4 [2.3–12.4]
ODI, events per hour 10.0 [4.3–19.0] 13.0 [3.8–28.3]
Mean oxygen saturation, % 93 [92–94] 94 [93–95]
Lowest desaturation, % 83 [80–86] 82 [82–85]
Continuous non-normally distributed variables are presented as median [25%
quartile−75% quartile]; AHI, apnoea-hypopnea-index; AI, apnoea index; BMI, body mass
index; CAD, coronary artery disease; cAI, central apnoea index; HI, hypopnea index; MI,
myocardial infarction; oAI, obstructive apnoea index; ODI, oxygen desaturation index; *p<
0,05; ¶p < 0,01; Mann-Whitney U test was used for non-normally distributed data.
1%. We observed no sustained VT or ventricular fibrillation
and no high-grade AV block and asystole episodes during
Holter monitoring in any patient. nsVT was detected in 20
patients. Comparing to patients without nsVT, patients with
nsVT had a significantly higher incidence of hypertension,
diabetes mellitus, and significantly lower ejection fraction.
Detailed characteristics of the patients with and without
detected nsVT are given in Table 4. We did not observe a
statistically significant impact of AHI, oAI, or HI of any
severity on nsVT. AI of 15 and more events per hour
and cAI of 10 and more events per hour was statistically
significant and associated with higher occurrence of nsVT in
the binary regression analysis (Figure 3). We included these
parameters, the hypoxia parameters as well as “hypertension,”
“diabetes mellitus” and “ejection fraction,” which differed
significantly between the groups in the univariate statistical
analysis with and without occurred nsVT in the multiple
binary regression analysis. We found a significant independent
association of AI of 23 and more events per hour, LVEF
<35% and hypertension with higher risk of the nsVT
occurrence (Figure 4).
LVEF was statistically significant and inversely proportionally
associated with AI and cAI (Pearson correlation index −0.16
[p = 0.026] and −0.17 [p = 0.017]. There was no correlation
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FIGURE 3 | Association between different cut-off values of apnoea index (AI)
and central apnoea index (cAI) and risk for non-sustained ventricular
tachycardia. OR-odds ratio; CI-confidence interval.
FIGURE 4 | Independent predictors for occurrence of non-sustained
ventricular tachycardia in study patients. OR-odds ratio; CI-confidence interval.
between LVEF and AHI and oAI. Mean cAI was 4.0 ± 7.2 1/h
in patients with LVEF ≥ 50% and 6.2 ± 12.0 1/h in patients with
EF <50% (p= 0.89).
DISCUSSION
We found high prevalence of SDB in the subacute phase after
uncomplicated AMI, which was markedly increased compared
to the general population (23). Similarly, high SDB prevalence
has been already observed in previous studies reporting data
of patients in the subacute phase after AMI (6–9, 24, 25).
Noteworthily, a comparison between different studies in terms
of reported SDB prevalence is often difficult, because discrepant
definitions for SDB, and its severity have been used. The
predominant SDB type in our study collective was CSA. Existing
scientific literature describing prevalence of CSA after AMI is
limited, mainly because the cardiorespiratory sleep monitoring
devices used did not differentiate between the different types
of SDB (6, 15, 16). Available studies reported either a similar
prevalence of CSA and OSA (6, 26) or a predominance of OSA
(15). Only few studies have reported CSA as a predominant SDB
type after AMI or acute coronary syndrome (27, 28). CSA is
common in patients with congestive heart failure and mainly
correlated with significantly impaired LVEF. Previous studies
demonstrated attenuation of CSA severity when LVEF improved
(29–31). Based on the findings, impaired LVEF could be a major
reason for the observed high CSA prevalence in our study
collective. However, several pathophysiological mechanisms in
the post-AMI period beyond the impairment of LVEF could
cause CSA pulmonary venous congestion, which can contribute
to dilated, and disturbed answer of chemical breathing controller
on changes in homeostasis (32), increased sympathetic activity
(27), and impaired autonomic cardiac nerve activity (13, 32, 33).
Autonomic alterations are associated with SDB, which play an
important role in the developing of atrial cardiomyopathy that
may represent a pathogenic factor for occurrence of ischemic
stroke (34). Although we detected a statistically significant
inversely proportional association between LVEF and CAI
consistent with the findings of the afore mentioned studies, the
mean CAI did not differ significantly between patients with
preserved or mildly-impaired LVEF compared to patients with
moderate to severe-impaired LVEF in our study. This is a novel
finding suggesting that pathophysiological changes occurring
after AMI could cause SDB and in particular CSA independent
from the LVEF impairment.
Though the prevalence of SDB after AMI is high, studies
investigating its impact on cardiovascular outcomes are scarce.
We observed statistically significant independent impact of
severe CSA on the prevalence of nsVT in the subacute phase
after uncomplicated AMI with preserved mean LVEF. Preserved
LVEF and revascularized culprit vessel would be possible reasons
for the very low incidence of atrial fibrillation and absence of
sustained VT, ventricular fibrillation, or high-grade bradycardic
arrhythmias in our study collective. The presence or severity of
OSA had no impact on the prevalence of nsVT. These are novel
findings, which have not been reported. Our results suggest that
only severe SDB is associated with higher arrhythmogenesis in
the subacute phase after AMI. In our study, only 15 patients
(7.4%) would be at higher risk for nsVT occurrence, when
we consider the observed cut-off value of AI = 23/h as an
independent risk margin. The exact mechanism linking SDBwith
arrhythmogenesis remains to be elucidated. However, several
pathophysiologic considerations suggest possible link between
CSA and arrhythmias: periodic alterations in ventilation promote
oscillations in blood pressure and heart rate (35), which can
promote higher cardiac workload and arrhythmias. Periodic
hypoxia during and after the apnoea phases causes an increase in
sympathetic nerve activity, which is a potentially arrhythmogenic
feature (36). Hypoxia itself as a consequence of SDB has been
shown to be associated with cardiac arrhythmias (37). Moreover,
patients with CSA hyperventilate, causing hypocapnia (38), and
sympathetic nerve activity increases more during hypocapnic
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hypoxia compared to isocapnic hypoxia (39). Acknowledging
the possible important role of hypoxia in arrhytmogenesis,
we analyzed the impact of hypoxia parameters (ODI, mean
saturation level, and highest desaturation, time with saturation
below 90%) on nsVT. We did not observe any significant
association between the hypoxia parameters, and nsVT in our
study collective. Arousals contribute to autonomic disturbance
and enhance sympathetic activity (40). Some evidence points
to the deterioration of cardiac hemodynamics caused by CSA
although the association is not as clear as inOSA, which generates
negative intrathoracic pressure. Yagishita-Tgawa et al. observed
more paroxysmal nocturnal dyspnea and increased levels of atrial
natriuretic peptide in patients with heart failure and predominant
CSA compared to those with predominant OSA (41). Previous
studies demonstrated the association between severe SDB and
the prevalence of nsVT not only in patients with congestive
heart failure or already known SDB, but also in the general
population (42–44). Our results suggest the possible association
of severe SDB with arrhythmogenesis beyond the impact of
impaired LVEF in a collective of patients with uncomplicated
AMI, which has not been described so far. Therefore, our data
support the afore mentioned pathophysiologic considerations
regarding the link between CSA and arrhythmogenesis and
extend the evidence as the majority of available data come
from patients with congestive heart failure. Thus, it would be
a reasonable consideration to screen patients after AMI for
SDB and–in case severe SDB would be detected–to monitor its
course and its association with arrhythmias in the long-term
follow up.
Limitations
We acknowledge several limitations of the study: PG and not
polysomnography (which includes EEG monitoring) has been
used in the sleep studies and the total sleep time was not
measured based on detection of the sleep stages by EEG, which
can potentially bias the calculation of sleep apnoea severity
indices. Another major limitation is that we did not classify
hypopnea events as central or obstructive, which could bias the
overall prevalence rates of CSA and OSA. Though consensus
definitions for obstructive and central hypopnea exist, they
are sophisticated and require standardization and validation.
Many indicators such as paradoxical movement, snoring, and
inspiratory flattering need to be included for distinction between
obstructive and hypopnea event. These indicators require
visual interpretation and definition of exact cut-offs, which are
not yet defined, and would increase interobserver variation
significantly. Moreover, some of these factors can easily be
confounded, like snoring, which can be confused with several
non-snoring sounds, and change in distance between sensor
and nose/mouth. In this context and acknowledging the low
median CAI of the study population, the observed significant
impact of CAI on arrhythmogenesis could attenuate or become
non-significant once hypopneas would be classified in central,
and obstructive and the prevalence rate of CSA and OSA
would change.
Potential arrhythmogenic factors caused by an AMI event
itself could not completely be ruled out, although fully
revascularisation of the culprit vessel, and the impact of
LVEF as potential important factors were considered in
the analysis.
CONCLUSION
Prevalence of SDB is high and CSA is the predominant type of
SDB in the collective of patients with uncomplicated AMI treated
with modern revascularization techniques and evidence-based
pharmacological therapy. Severe SDB is independently associated
with a higher risk of nsVT and its course should be monitored as
it is a comorbidity, which potentially has negative impact on the
relevant outcomes of AMI patients. Further prospective studies
are needed to assess long-term follow up of SDB after AMI, and
its impact on mortality and morbidity.
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